Patient-Driven Gene Therapy Company ReflectionBio Receives Orphan Drug Designation From U.S. FDA For the Treatment of Bietti’s Crystalline Dystrophy (BCD)
HONG KONG & NEW YORK--(BUSINESS WIRE)--Reflection Biotechnologies Limited ("ReflectionBio"), a gene therapy company committed to the research and development of life-changing treatments for rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to ReflectionBio's RBIO-101 program (AAV.CYP4V2), an AAV-based gene therapy product for treating Bietti's Crystalline Dystrophy (BCD). "Receiving orphan drug designation from the FDA is a miles